1. Explain the general nature of inter-patient and intra-tumoral heterogeneity in triple-negative breast cancer.

2. Identify recently FDA-approved therapy and remaining unmet medical needs in TNBC.

Event address for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=e9719cf345e9a5880da9a903fdf04524f

Session date: 
11/18/2020 - 8:00am to 9:00am CST
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Leif W. Ellisen, MD, PhD